Stenson W F, Cort D, Rodgers J, Burakoff R, DeSchryver-Kecskemeti K, Gramlich T L, Beeken W
Jewish Hospital of St. Louis, Missouri 63110.
Ann Intern Med. 1992 Apr 15;116(8):609-14. doi: 10.7326/0003-4819-116-8-609.
To determine the efficacy of fish oil supplementation in patients with active ulcerative colitis.
Multicenter, randomized, double-blind, placebo-controlled, crossover trail with 4-month treatment periods (fish oil and placebo) separated by a 1-month washout.
Four gastroenterology divisions.
Twenty-four patients with active ulcerative colitis entered the study. Five dropped out, and one was noncompliant. Eighteen patients completed the study. All patients had active disease as manifested by diarrhea and rectal inflammation.
Treatment with prednisone and sulfasalazine was continued. Fish oil supplementation consisted of 18 Max-EPA (eicosapentaenoic acid) capsules daily (eicosapentaenoic acid, 3.24 g; and docosahexaenoic acid, 2.16 g). Placebo supplementation consisted of 18 identical capsules containing isocaloric amounts of vegetable oil.
Patients were evaluated at study entry and after each diet period. Evaluations included a review of symptoms, flexible sigmoidoscopy, rectal biopsy, and rectal dialysis to measure prostaglandin E2 and leukotriene B4 levels.
Fish oil supplementation resulted in a significant decrease in rectal dialysate levels of leukotriene B4 from 71.0 to 27.7 pg/mL (average change, -43.3 pg/mL; 95% CI, -83 to -3.6). Significant improvements were seen in acute histology index (average change, -8.5 units from a baseline of 10.5 units; CI, -12.9 to -4.2) and total histology index (average change, -8.5 units from a baseline of 14.80; CI, -13.2 to -3.8) as well as significant weight gain (average weight gain, 1.74 kg, CI, 0.94 to 2.54). No significant changes occurred in any variable during the placebo period. Seven patients received concurrent treatment with prednisone. During the fish oil supplementation period, the mean prednisone dose decreased from 12.9 mg/d to 6.1 mg/d and rose from 10.4 mg/d to 12.9 mg/d during the placebo diet period (P greater than 0.20).
Four months of diet supplementation with fish oil in patients with inflammatory bowel disease resulted in reductions in rectal dialysate leukotriene B4 levels, improvements in histologic findings, and weight gain.
确定补充鱼油对活动性溃疡性结肠炎患者的疗效。
多中心、随机、双盲、安慰剂对照的交叉试验,治疗期为4个月(鱼油和安慰剂),中间有1个月的洗脱期。
四个胃肠病科。
24例活动性溃疡性结肠炎患者进入研究。5例退出,1例未依从。18例患者完成研究。所有患者均有以腹泻和直肠炎症为表现的活动性疾病。
继续使用泼尼松和柳氮磺胺吡啶治疗。补充鱼油为每日18粒Max-EPA(二十碳五烯酸)胶囊(二十碳五烯酸3.24 g;二十二碳六烯酸2.16 g)。补充安慰剂为18粒含有等热量植物油的相同胶囊。
在研究开始时和每个饮食期后对患者进行评估。评估包括症状回顾、乙状结肠镜检查、直肠活检以及测量前列腺素E2和白三烯B4水平的直肠透析。
补充鱼油使直肠透析液中白三烯B4水平从71.0 pg/mL显著降至27.7 pg/mL(平均变化-43.3 pg/mL;95%可信区间,-83至-3.6)。急性组织学指数(平均变化,从基线10.5单位下降8.5单位;可信区间,-12.9至-4.2)和总组织学指数(平均变化,从基线14.80下降8.5单位;可信区间,-13.2至-3.8)有显著改善,体重也显著增加(平均体重增加1.74 kg;可信区间,0.94至2.54)。在安慰剂期,任何变量均无显著变化。7例患者同时接受泼尼松治疗。在补充鱼油期间,泼尼松平均剂量从12.9 mg/d降至6.1 mg/d,在安慰剂饮食期从10.4 mg/d升至12.9 mg/d(P>0.20)。
炎症性肠病患者补充鱼油4个月可降低直肠透析液中白三烯B4水平,改善组织学结果,并使体重增加。